Top Page
PureTech Health
(LSE:PRTC)
PureTech Health (PRTC) vs. iShares MSCI United Kingdom ETF (EWC)
PureTech Health Business Overview & Revenue Model
PureTech Health Earnings Call Summary
PureTech Health Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.32M | 750.00K | 2.09M | 9.98M | 8.34M |
| Gross Profit | 4.32M | -92.91M | -150.34M | -100.49M | 8.34M |
| EBITDA | 37.38M | -17.68M | -79.94M | -46.95M | -144.76M |
| Net Income | 53.51M | -65.70M | -37.06M | -62.71M | 4.57M |
Balance Sheet | |||||
| Total Assets | 602.63M | 693.97M | 702.65M | 946.01M | 989.99M |
| Cash, Cash Equivalents and Short-Term Investments | 367.31M | 327.14M | 350.10M | 465.71M | 403.88M |
| Total Debt | 22.36M | 25.34M | 46.87M | 52.02M | 76.62M |
| Total Liabilities | 194.70M | 235.74M | 155.06M | 361.86M | 336.45M |
| Stockholders Equity | 414.71M | 464.07M | 542.22M | 593.51M | 669.75M |
Cash Flow | |||||
| Free Cash Flow | -134.38M | -106.16M | -180.97M | -163.94M | -137.25M |
| Operating Cash Flow | -134.37M | -105.92M | -178.79M | -158.27M | -131.83M |
| Investing Cash Flow | 240.89M | 68.99M | -107.22M | 197.38M | 364.48M |
| Financing Cash Flow | -16.96M | 78.14M | -29.83M | 22.73M | 38.87M |
PureTech Health Technical Analysis
PureTech Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £142.38M | 18.13 | 69.08% | 8.26% | 0.49% | -9.52% | |
62 Neutral | £1.41B | ― | -23.77% | ― | 7.97% | 12.94% | |
61 Neutral | £329.63M | 8.38 | 11.74% | ― | 38.80% | ― | |
60 Neutral | HK$17.01B | 5.47 | -7.44% | 4.37% | 11.55% | -28.15% | |
46 Neutral | £107.31M | ― | 167.16% | ― | -100.00% | -23.91% | |
| ― | $526.64M | ― | -66.23% | ― | ― | ― | |
39 Underperform | £152.53M | ― | -95.28% | ― | 84.39% | -41.02% |
PureTech Health Corporate Events
Seaport Therapeutics, a PureTech Health Founded Entity, announced the dosing of the first patient in the Phase 2b BUOY-1 study of GlyphAllo, a novel oral prodrug for treating major depressive disorder (MDD) with or without anxious distress. This study aims to evaluate the efficacy, safety, and tolerability of GlyphAllo, potentially positioning it as a first-in-class treatment for MDD. The trial builds on promising Phase 1 and 2a results, with the Glyph platform overcoming previous limitations of allopregnanolone’s clinical use, potentially impacting the treatment landscape for depression and anxiety.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health has announced a leadership transition with the stepping down of Bharatt Chowrira as CEO and the appointment of Robert Lyne as Interim CEO. Lyne, with his extensive experience in life sciences and venture capital, is expected to drive shareholder value and continue advancing PureTech’s high-value portfolio, building on the momentum of its programs to create value for patients and shareholders.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced a significant change in its board of directors as Raju Kucherlapati, PhD, steps down as Chair. Sharon Barber-Lui will serve as Interim Chair while leading the search for a new Chair, engaging with shareholders for input. This transition marks a pivotal moment for PureTech, which has evolved from a startup to an established biotherapeutics company under Dr. Kucherlapati’s guidance, known for its breakthrough medicines like the FDA-approved Cobenfy™.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced the vesting of restricted share units (RSUs) granted to certain directors and managerial staff as part of its Performance Share Plan, with 33% of the shares vesting on June 26, 2025. This issuance increased the company’s total issued ordinary share capital to 257,927,489 shares, with 16,611,162 held in treasury. The transaction reflects PureTech’s ongoing commitment to rewarding its leadership team and aligns with its strategic goals, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced the vesting of restricted share units (RSUs) awarded to certain non-executive directors under its Performance Share Plan. This resulted in the issuance of ordinary shares to these directors, impacting the company’s total share capital. The announcement highlights PureTech’s commitment to rewarding its leadership while maintaining transparency in its operations, potentially strengthening stakeholder confidence.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced that 25% of restricted share units granted to Robert Lyne, Chief Portfolio Officer, vested on February 1, 2025, with shares issued on July 1, 2025. The transaction involved the sale and subsequent purchase of 33,561 shares by Lyne, reflecting strategic financial management and potentially impacting shareholder dynamics.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced its total voting rights and share capital as of June 30, 2025, with 257,927,489 issued ordinary shares and 17,673,040 shares held in treasury, resulting in 240,254,449 voting rights. This information is crucial for shareholders to assess their interests in the company under regulatory guidelines, impacting their decision-making and compliance with disclosure rules.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Vor Bio, a company founded by PureTech Health, has entered into an exclusive global license agreement with RemeGen to develop and commercialize telitacicept, a dual-target fusion protein for autoimmune diseases, outside of Greater China. This agreement includes an initial payment of $125 million and potential milestones exceeding $4 billion. Additionally, Vor Bio announced a $175 million private placement to support the development of its clinical pipeline, marking a significant step in its growth strategy and positioning in the autoimmune treatment market.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced that all resolutions at its Annual General Meeting were passed, though resolutions on directors’ remuneration and the re-election of Ms. Kiran Mazumdar-Shaw received less than 80% approval. The company emphasizes its commitment to engaging with shareholders on remuneration and governance issues, promising an update within six months in line with the UK Corporate Governance Code 2024.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health PLC has announced a change in the nature of attribution due to a reduction in the Right to Recall securities, following an acquisition or disposal of voting rights and financial instruments by Citigroup Inc. This adjustment has resulted in Citigroup holding a total of 5.410498% of voting rights in PureTech, indicating a slight increase from the previous position, which may impact the company’s shareholder dynamics and influence.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced that its CEO, Bharatt Chowrira, and Co-founder, Eric Elenko, will participate in a fireside chat at the Jefferies Global Healthcare Conference. This participation highlights PureTech’s active engagement in the healthcare industry and may enhance its visibility and influence among stakeholders and potential investors.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced promising results from its Phase 2b ELEVATE IPF trial for deupirfenidone (LYT-100), a potential new treatment for idiopathic pulmonary fibrosis (IPF). The trial demonstrated that deupirfenidone significantly slowed lung function decline compared to placebo, with a favorable safety profile. The treatment effect was sustained over 52 weeks, suggesting its potential to become a new standard of care for IPF. PureTech plans to meet with the FDA to discuss a Phase 3 trial, aiming to initiate it by the end of 2025. These findings could position PureTech as a leader in IPF treatment, offering a differentiated option for patients and potentially impacting the market for current standard-of-care treatments.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health has published new research in collaboration with experts and the Pulmonary Fibrosis Foundation, revealing critical gaps in the diagnosis, treatment, and quality of life for individuals with idiopathic pulmonary fibrosis (IPF). The study highlights the need for enhanced education, patient-focused treatment plans, and more effective therapies, emphasizing the importance of integrating patient perspectives into care strategies to improve outcomes and quality of life for those affected by IPF.
PureTech Health announced that it will present results from its Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) at the American Thoracic Society International Conference. The trial demonstrated significant efficacy in stabilizing lung function decline in idiopathic pulmonary fibrosis (IPF) patients over 26 weeks, suggesting deupirfenidone could become a new standard of care. The company plans to meet with the FDA to discuss a potential Phase 3 trial by the end of 2025, aiming to provide a transformative treatment option for IPF patients.
PureTech Health announced significant achievements in 2024, including FDA approval for Cobenfy™, positive Phase 2b results for deupirfenidone in IPF, and promising data for LYT-200 in cancer treatment. The company’s financial strength is underscored by a robust cash position, supporting operations through 2027. PureTech’s strategic focus is on advancing its pipeline, securing external funding for Phase 3 trials, and maintaining capital efficiency to drive long-term growth and shareholder value.